Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 9/20 | 0.55 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.46 |
| ▸ | BMP1 | P13497 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409599 | 0.95 | TDP1 (0.58) | LPAR1LPAR5TDP1TP53THRB | |
| SCHEMBL5395922 | 0.92 | TDP1 (0.55) | LPAR1LPAR5TDP1TSHRKMT2A | |
| SCHEMBL5409849 | 0.92 | KMT2A (0.49) | LPAR1TP53THRBTSHRKMT2A | |
| SCHEMBL5399038 | 0.91 | LPAR1 (0.50) | LPAR1LPAR5TDP1TP53THRB | |
| SCHEMBL5418587 | 0.91 | LPAR1 (0.58) | LPAR1LPAR5TDP1TSHRKMT2A | |
| SCHEMBL5400875 | 0.90 | LTB4R2 (0.45) | LPAR1LPAR5TP53THRBTSHR | |
| SCHEMBL5399052 | 0.90 | LPAR1 (0.50) | LPAR1LPAR5TDP1TP53THRB | |
| SCHEMBL5402445 | 0.90 | TDP1 (0.52) | LPAR1LPAR5TDP1TSHRKMT2A | |
| SCHEMBL5402609 | 0.89 | LPAR1 (0.59) | LPAR1LPAR5TDP1TSHRALOX5 | |
| SCHEMBL5412182 | 0.89 | KMT2A (0.47) | LPAR1TSHRKMT2AMEN1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | LPAR1 17/4885LPAR5 125/4885TDP1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.